Method of treating catabolic dysfunction

Abstract

The invention relates to a method of treating a catabolic dysfunction in an animal, which comprises administering to an animal a therapeutically effective amount of glutamine, or an analog thereof.

What is claimed as new and is desired to be covered by Letters Patent is: . .1. A method of treating catabolic dysfunction in an animal, which comprises administering to said animal a therapeutically effective amount of glutamine or an analogue thereof in an amount greater than that present in the normal diet of said animal..!.. .2. The method of claim 1 wherein said catabolic dysfunction is enteral or parenteral..!.. .3. The method of claim 2 wherein said enteral dysfunction occurs substantially associated with intravenous feeding..!.. .4. The method of claim 3 wherein said 
     
        enteral dysfunction affects the small intestine..!.. .5.  The method of claim 2 wherein said parental dysfunction occurs substantially associated with physical trauma..!.. .6. The method of claim 5 wherein said physical trauma is associated with surgery, sepsis, burn injuries, anorexia, chemotherapy, radiation therapy, or uncontrolled diabetes..!.. .7. The method of claim 1 wherein said administration of a therapeutically effective amount of glutamine is enteral or parenteral..!.. .8. The method of claim 7 wherein said administration is by use of a dietary supplement..!.. .9. The method of claim 7 wherein said parenteral administration is by subcutaneous, intramuscular, or intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption..!.. .10. The method of claim 8 wherein said enteral administration is at the rate of 0.3 to 2.0 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .11. The method of claim 10 wherein said enteral administration is at the rate of 0.3 to 1.5 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .12. The method of claim 11 wherein said enteral administration is at the rate of 0.4 to 1.0 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .13. The method of claim 9 wherein said parenteral administration is at the rate from 0.2 to 3.0 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .14. The method of claim 13 wherein said parenteral administration is at the rate from 0.3 to 2.5 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .15. The method of claim 14 wherein said parenteral administration is at the rate from 0.4 to 2.0 grams of glutamine or glutamine analogue per kilogram of body weight per day..!.. .16. A composition comprising a glutamine-rich composition for preventing or ameliorating a catabolic dysfunction..!.. .17. A container for a liquid composition adapted for intravenous administration of said composition, comprising a receptacle for said composition, and liquid conducive means connected to said receptacle capable of attachment to a needle for intravenous dispensation, wherein said composition comprises an amount of glutamine capable of inhibiting a catabolic dysfunction in an animal..!.. .18. The container of claim 17 wherein said catabolic 
     
     
        dysfunction is associated with skeletal muscle wasting..!..Iadd.19.  The method of treating atrophy of skeletal muscle, intestinal mucosa, or both in an animal, which comprises enterally administering to said animal a therapeutically effective amount of glutamine or a functional analogue thereof which retains the characteristics of glutamine in an amount greater than that present in the normal diet of said animal wherein said therapeutically effective amount of glutamine or a functional derivative 
     
     
        thereof is 0.4-3.0 g/kg/day. .Iaddend..Iadd.20.  The method of claim 19 which comprises inhibiting atrophy of intestinal mucosa. .Iaddend..Iadd.21. The method of claim 20 wherein said atrophy of intestinal mucosa occurs substantially associated with intravenous feeding. .Iaddend..Iadd.22. The method of claim 19 which comprises inhibiting atrophy of skeletal muscle. .Iaddend..Iadd.23. The method of claim 22 wherein said atrophy of skeletal muscle occurs substantially associated with physical trauma. .Iaddend..Iadd.24. The method of claim 23 wherein said physical trauma is associated with surgery, sepsis, burn injuries, anorexia, chemotherapy, radiation therapy, or uncontrolled 
     
     
        diabetes. .Iaddend..Iadd.25.  The method of claim 19 wherein said 
     
     
        administration is by use of a dietary supplement. .Iaddend..Iadd.26.  The method of claim 19 wherein said enteral administration is at the rate of 0.4 to 2.0 grams of glutamine or glutamine analogue per kilogram of body weight per day. .Iaddend..Iadd.27. The method of claim 26 wherein said enteral administration is at the rate of 0.4 to 1.5 grams of glutamine or glutamine analogue per kilogram of body weight per day. 
     
     
        .Iaddend..Iadd.     A method according to claim 26, wherein said enteral administration is at the rate of 0.4 to 1.0 grams of glutamine or glutamine analogue per kilogram of body weight per day. .Iaddend.